Acumen Pharmaceuticals, Inc. - Common Stock (ABOS)

Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outstanding shares is at $87.2 million.

ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.

Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a broader market where technology rules.

ABOS stock results show that Acumen Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.

ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.

Healthcare stocks to buy are not talked about as much right now, but are great stocks investors should consider adding.

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.

These three aging stocks offer different thematic approaches to profit from the opportunities that exist in an aging population.

ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market.

Biotech companies are edging closer to finding the answers behind Alzheimer's disease.

Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.

Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.